Prediction of area under the concentration–time curve for lopinavir from peak or trough lopinavir concentrations in patients receiving lopinavir–ritonavir therapy-Reference-Cited by-同舟云学术

Prediction of area under the concentration–time curve for lopinavir from peak or trough lopinavir concentrations in patients receiving lopinavir–ritonavir therapy

Published:2016-03-15 Issue:6 Volume:73 Page:376-385
ISSN:1079-2082
Container-title:American Journal of Health-System Pharmacy
language:en
Short-container-title:

Author:

Srinivas Nuggehally R.¹

Affiliation:

1. Suramus Bio, Bangalore, India

Publisher

Oxford University Press (OUP)

Subject

Health Policy,Pharmacology

Link

http://academic.oup.com/ajhp/article-pdf/73/6/376/28334999/ajhp0376.pdf

Reference57 articles.

1. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy;Gazzard;HIV Med,2008

2. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society–USA panel;Hammer;JAMA,2008

3. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study;Molina;Lancet,2008

4. A pharmacokinetic model of lopinavir in combination with ritonavir in humans;Duangchaemkarn;Conf Proc IEEE Eng Med Biol Soc,2014

5. Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4;Rock;Mol Pharmacol,2014

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Area under the curve predictions of dalbavancin, a new lipoglycopeptide agent, using the end of intravenous infusion concentration data point by regression analyses such as linear, log-linear and power models;Xenobiotica;2017-03-14